Maximum Effective Dose of 5-Fluorouracil
The maximum tolerated dose of 5-FU varies by administration schedule: for bolus regimens, 475 mg/m²/day for 5 days is the MTD, while for continuous infusion regimens, doses up to 3,750 mg/m²/48 hours weekly are tolerable, though the recommended dose for phase II trials is 700-800 mg/m²/day for continuous infusion. 1, 2, 3
Dose by Administration Schedule
The maximum effective dose of 5-FU that remains tolerable is fundamentally dependent on the administration method:
Bolus Administration
- MTD: 475 mg/m²/day (days 1-5) when combined with leucovorin 100 mg/m² 1
- Dose-limiting toxicities: stomatitis and diarrhea
- More pronounced myelosuppression compared to infusion schedules
- Starting dose typically 400 mg/m²/day with escalation by 50 mg/m²/day until individual MTD reached
Continuous Infusion (48-hour)
- MTD: 3,750 mg/m²/48 hours/week in tri-monthly schedules 2
- Recommended dose: 3,500 mg/m²/48 hours/week for future trials 2
- Dose-limiting toxicities: grade III neutropenia, mucositis, diarrhea, and hand-foot syndrome lasting >3 days
- Achieves steady-state plasma concentration of 8.06 ± 6.39 μmol/L with significantly lower bone marrow concentrations (2.89 ± 1.01 μmol/L), explaining reduced myelotoxicity 2
Continuous Infusion (Daily)
- MTD: 800 mg/m²/day for 5 consecutive days 3
- Recommended dose: 700 mg/m²/day for phase II trials 3
- Dose-limiting toxicities: mucositis and diarrhea
Critical Dosing Considerations
DPYD Genotype Impact
Patients with DPYD variants require substantial dose reductions (25-50% depending on specific variant) to avoid severe toxicity 4, 5. The FDA label explicitly contraindicates 5-FU in patients with complete DPD deficiency 5. However, the 2024 NCCN guidelines do not recommend universal pretreatment DPYD genotyping due to concerns about potential efficacy reduction with dose adjustments, particularly in the adjuvant setting 4.
Schedule-Dependent Pharmacokinetics
Infusional regimens are less toxic than bolus regimens and should be preferentially used 6. The standard FOLFOX regimen uses oxaliplatin 85 mg/m² every 2 weeks (not higher doses, as there is no evidence of increased activity) 6. For CAPOX, the dose is capecitabine 2,000 mg/m²/day for days 1-14 every 3 weeks with oxaliplatin 130 mg/m² 6.
Common Pitfalls
- Avoid bolus regimens when infusional options are available - they carry higher toxicity without superior efficacy 6
- Do not exceed 85 mg/m² oxaliplatin in FOLFOX - higher doses lack evidence of benefit 6
- Individual dose escalation is appropriate - in the absence of dose-limiting toxicity and progressive disease, escalate by 50 mg/m²/day per cycle until individual MTD is reached 1
- Weekly schedules with doses ≥720 mg/m² are critical - higher doses show no additional benefit and increase severe side effects 7